000180126 001__ 180126
000180126 005__ 20240229145607.0
000180126 0247_ $$2doi$$a10.3390/ijms23105857
000180126 0247_ $$2pmid$$apmid:35628668
000180126 0247_ $$2ISSN$$a1422-0067
000180126 0247_ $$2ISSN$$a1661-6596
000180126 0247_ $$2altmetric$$aaltmetric:128977907
000180126 037__ $$aDKFZ-2022-01119
000180126 041__ $$aEnglish
000180126 082__ $$a540
000180126 1001_ $$aMurad, Shafiq$$b0
000180126 245__ $$aNKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme.
000180126 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2022
000180126 3367_ $$2DRIVER$$aarticle
000180126 3367_ $$2DataCite$$aOutput Types/Journal article
000180126 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1653988994_21817
000180126 3367_ $$2BibTeX$$aARTICLE
000180126 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180126 3367_ $$00$$2EndNote$$aJournal Article
000180126 520__ $$aIn glioblastoma, non-classical human leucocyte antigen E (HLA-E) and HLA-G are frequently overexpressed. HLA-E loaded with peptides derived from HLA class I and from HLA-G contributes to inhibition of natural killer (NK) cells with expression of the inhibitory receptor CD94/NKG2A. We investigated whether NK cells expressing the activating CD94/NKG2C receptor counterpart were able to exert anti-glioma effects. NKG2C+ subsets were preferentially expanded by a feeder cell line engineered to express an artificial disulfide-stabilized trimeric HLA-E ligand (HLA-E*spG). NK cells expanded by a feeder cell line, which facilitates outgrowth of conventional NKG2A+, and fresh NK cells, were included for comparison. Expansion via the HLA-E*spG feeder cells selectively increased the fraction of NKG2C+ NK cells, which displayed a higher frequency of KIR2DL2/L3/S2 and CD16 when compared to expanded NKG2A+ NK cells. NKG2C+ NK cells exhibited increased cytotoxicity against K562 and KIR:HLA-matched and -mismatched primary glioblastoma multiforme (GBM) cells when compared to NKG2A+ NK cells and corresponding fresh NK cells. Cytotoxic responses of NKG2C+ NK cells were even more pronounced when utilizing target cells engineered with HLA-E*spG. These findings support the notion that NKG2C+ NK cells have potential therapeutic value for treating gliomas.
000180126 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000180126 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180126 650_7 $$2Other$$aHLA-E
000180126 650_7 $$2Other$$aHLA-G
000180126 650_7 $$2Other$$aNK cells
000180126 650_7 $$2Other$$abrain cancer
000180126 650_7 $$2Other$$aglioblastoma
000180126 650_7 $$2Other$$aimmunotherapy
000180126 7001_ $$00000-0002-5726-386X$$aMichen, Susanne$$b1
000180126 7001_ $$aBecker, Alexander$$b2
000180126 7001_ $$aFüssel, Monika$$b3
000180126 7001_ $$aSchackert, Gabriele$$b4
000180126 7001_ $$aTonn, Torsten$$b5
000180126 7001_ $$0P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aMomburg, Frank$$b6$$udkfz
000180126 7001_ $$00000-0001-5084-1180$$aTemme, Achim$$b7
000180126 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms23105857$$gVol. 23, no. 10, p. 5857 -$$n10$$p5857$$tInternational journal of molecular sciences$$v23$$x1422-0067$$y2022
000180126 909CO $$ooai:inrepo02.dkfz.de:180126$$pVDB
000180126 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b2290261145f21c46f2d42783c69d104$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000180126 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000180126 9141_ $$y2022
000180126 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000180126 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000180126 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000180126 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000180126 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000180126 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000180126 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-04T08:27:04Z
000180126 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-04T08:27:04Z
000180126 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-09-04T08:27:04Z
000180126 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2021$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2022-11-25
000180126 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J MOL SCI : 2021$$d2022-11-25
000180126 9201_ $$0I:(DE-He78)D121-20160331$$kD121$$lD121 AG Antigenpräsentation und T/NK-Zell-Aktivierung$$x0
000180126 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x1
000180126 980__ $$ajournal
000180126 980__ $$aVDB
000180126 980__ $$aI:(DE-He78)D121-20160331
000180126 980__ $$aI:(DE-He78)D120-20160331
000180126 980__ $$aUNRESTRICTED